Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples

Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples

Cenobamate (CNB) is the newest antiseizure medication (ASM) approved by the FDA in 2019 to reduce uncontrolled partial-onset seizures in adult patients. Marketed as Xcopri in the USA or Ontozry in the EU (tablets), its mechanism of action has not been fully understood yet; however, it is known that...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Bruno Charlier, Albino Coglianese, Francesca Felicia Operto, Giangennaro Coppola, Ugo de Grazia, Pierantonio Menna, Amelia Filippelli, Fabrizio Dal Piaz, Viviana Izzo
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: MDPI AG 2022-10-01
Sarja:Molecules
Aiheet:
antiseizure medications
UHPLC–MS/MS
liquid chromatography
mass spectrometry
cenobamate
therapeutic drug monitoring
Linkit:https://www.mdpi.com/1420-3049/27/21/7325

Internet

https://www.mdpi.com/1420-3049/27/21/7325

Samankaltaisia teoksia